About
Tarsier Pharma is a late-clinical-stage company dedicated to the development and commercialization of a breakthrough therapeutic approach for better and safer treatment of autoimmune inflammatory ocular diseases. The TRS Platform Technology is a bio-inspired immunomodulator designed to treat blinding inflammatory ocular diseases. It is currently being developed as both eye drops and intravitreal injections. TRS has the potential to effectively control a range of autoimmune and inflammatory ocular diseases as potently as steroids but without the negative side effects. The company's investors include a wholly owned subsidiary company of Sun Pharmaceutical Industries Limited, BioLight Life Sciences Ltd, as well as private investors and family offices. The company has also received funding from the European Union's Horizon 2020 research and innovation program under grant agreement No. 879598.
Headcount over time
Offices
Q&A
- What is Tarsier Pharma's primary focus?
- Tarsier Pharma is a late-clinical-stage company dedicated to developing and commercializing therapeutic approaches for autoimmune inflammatory ocular diseases.
- What is the status of Tarsier Pharma's TRS01 program?
- In December 2020, Tarsier Pharma had a positive End-of-Phase 2 meeting with the U.S. FDA, setting the stage for its TRS01 Phase III program in uveitis.
- Has Tarsier Pharma received any significant grants?
- In September 2019, Tarsier Pharma received a grant of $2,616,894. The company also received funding from the European Union's Horizon 2020 research and innovation program.
- What is the latest development regarding Tarsier Pharma's product pipeline?
- In August 2022, Tarsier Pharma announced the development of TRS02, a potential immunomodulator with a sustained-release intravitreal formulation for the treatment of retinal diseases.
- What is the employee count for Tarsier Pharma?
- Tarsier Pharma has an employee count in the 11-50 range.
- What is the total amount of capital Tarsier Pharma has raised to date?
- Tarsier Pharma has raised a total of $5,650,000 USD.
- What is the current stage of Tarsier Pharma's product development?
- Tarsier Pharma's product is in the clinical trial stage.
- When was Tarsier Pharma founded?
- Tarsier Pharma was founded in January 2016.
Team · 16
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | tarsierpharma.com |
|---|---|
| linkedin.com/company/34220421 |
Identifiers & details
| Legal name | Tarsier Pharma Ltd. |
|---|---|
| Former names | Tarsius Pharma |
| Founded | 2016-1 |
| Employees (exact) | 12 |
Radar intelligence
Patents
| EPO | 6 |
|---|
Web history (Wayback)
| Domain | tarsierpharma.com |
|---|
Certificate / subdomain footprint
| Subdomains | 12 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 515398642 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2016-02-21 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2026 |
| Active charges / liens | 0 |
| Registry events | 5 — annual_report (4), people (1) |
| Registered address | המעפילים 10 זכרון יעקב |
Recent registry events
| Date | Event |
|---|---|
| 2026-06-24 | דו~ח שנתי-הקצאת מניות |
| 2026-02-23 | דו~ח שנתי-שינוי בהוראות בתקנון |
| 2026-02-23 | דו~ח שנתי-עדכון מען דיגיטלי |
| 2026-02-23 | דו~ח שנתי-עדכון כתובת |
| 2026-01-14 | עדכון בעלי תפקידים |